logo
How First-Time Job Seekers Can Negotiate Without Settling For Less

How First-Time Job Seekers Can Negotiate Without Settling For Less

Forbes2 days ago
Negotiation isn't just for seasoned pros. First-time job seekers can secure better offers by staying ... More clear, calm, and confident during the conversation.
Landing your first full-time role is exciting, but once the offer comes in, it's easy to go from proud to panicked. Should you negotiate? Are you even allowed to? What if asking for more makes them pull the offer altogether? These fears are common, but here's the truth: negotiation isn't just for seasoned professionals.
In fact, negotiating early in your career helps set the tone for your long-term growth and shows potential employers that you understand your value. The key is knowing how to approach it without letting fear get in your way.
Here are a few lesser-known but powerful strategies that can help you negotiate your first job offer with confidence and without overstepping or second-guessing yourself.
Start By Reframing What Negotiation Really Means
Most first-time job seekers think negotiation is about demanding more. In reality, it's a collaborative conversation about fit and fairness. You're not begging for a favor. You're starting a dialogue about how you and the employer can both thrive. The mindset shift here is essential. Rather than seeing yourself as 'lucky' to have any offer, understand that you're bringing skills, energy, and potential to the table. You're not a burden, but an asset. Negotiation is about alignment, not arrogance.
Learn To Talk About Money Without Apologizing
One of the biggest mistakes new professionals make is treating salary like a dirty word. If you tiptoe around the topic, apologize for asking, or over-explain why you need a higher number, you dilute your power. Practice saying something simple like, 'Based on my research and the scope of this role, I was hoping we could explore a starting salary closer to [your number]
Practice Saying The Number Out Loud
It sounds simple, but this one works. Before the conversation, get used to hearing your ask in your own voice. Practice in the mirror, say it to a friend, or record yourself. The more familiar the number becomes to you, the easier it'll be to say without flinching. When you hesitate or stumble, it signals uncertainty. But when you say your number like it's just a fact (and it is), you remove the emotional charge and let your confidence do the talking.
Signal That You're Serious, Not Desperate
There's a fine line between eagerness and desperation. You want to show enthusiasm for the role, but you don't want to come across like you'll take anything they offer. Desperation reads as a lack of options, which can weaken your position. Instead, say something like, 'I'm really excited about this opportunity, and I want to make sure it's a strong fit on both sides.' This keeps the conversation balanced and makes it clear you're thinking long term, not just rushing to say yes.
Build Your Leverage With Quiet Confidence
If you don't have other offers, that doesn't mean you're out of leverage. Your strengths, your potential, and the way you carry yourself all contribute. Be ready to speak about what you bring to the team, even if your experience is limited. Focus on your problem-solving skills, your initiative, and your adaptability. You don't need a 10-year resume to prove you're valuable. You just need to show you've done your homework and that you're prepared to make an impact.
Make The Conversation About Mutual Fit
Hiring isn't charity, it's strategy. The employer is choosing someone who will add value to their team. Your goal in a negotiation is to reinforce why you're that person. Keep the tone collaborative. Try: 'I want this to be a great long-term fit, and I believe I can contribute a lot in this role. Would it be possible to revisit the compensation so that it reflects the value I'm ready to bring?' This keeps the conversation focused on partnership, not personal need.
Use A Future-Focused Mindset
One reason many first-time job seekers hesitate to negotiate is that they're worried about 'messing it up.' But here's the thing: you're not just negotiating for this role, you're setting a standard for the roles that come after. Even if you only increase your salary by $2,000, that raise compounds across every future offer that builds off this one. You're not being difficult. You're being smart. Think beyond your starting paycheck and focus on the precedent you're setting.
Accepting an offer without negotiation doesn't make you easier to work with; it can make you easier to undervalue. The act of negotiating, when done respectfully, sends a signal that you take your career seriously. It shows that you understand boundaries, goals, and self-advocacy, which are all qualities of a strong employee. This isn't about pushing for the moon. It's about setting a foundation you can build on.
Negotiating your first offer is about honoring yourself. You've put in the work, the interviews, the waiting. Now is the moment to speak up with clarity and calm. Even if the number doesn't change, the act of asking will teach you something powerful: your voice matters. Practice using it now, and you'll carry that skill for the rest of your career. You've got this!
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever
Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever

Yahoo

time9 minutes ago

  • Yahoo

Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever

Key Points Johnson & Johnson has a historically high yield, and it is a Dividend King. Medtronic is two years shy of Dividend King status and has a historically high yield. Merck's dividend has grown steadily, though not annually, for decades. 10 stocks we like better than Johnson & Johnson › Healthcare stocks aren't exactly known for offering large yields, with the average healthcare stock at just 1.8% or so. You can do better than that and get reliable dividend stocks while you are at it. All you need to do is buy Johnson & Johnson (NYSE: JNJ), Medtronic (NYSE: MDT), and Merck (NYSE: MRK), and then hold them forever. Here's what you need to know. 1. Johnson & Johnson is a Dividend King When it comes to reliable dividend stocks, the highest honor that is bestowed on a company is the rank of Dividend King. A company has to increase its dividend annually for five decades to earn that title. Johnson & Johnson's dividend streak is up to 63 years, which is the longest streak of any healthcare company. The dividend yield is an attractive 3.1%. That yield is not only well above the healthcare average, it's also toward the high end of Johnson & Johnson's historical yield range. Historically speaking, the stock looks like it is on sale despite what is a very impressive and well-run business. The company is an industry-leading pharmaceutical and medical device maker. That said, there's a bit of uncertainty here today. Johnson & Johnson is facing a fairly large class action lawsuit around talcum powder it sold. It will likely survive through this, but the overhang of the suit could be a drag for a while. If that doesn't bother you, though, jump in. One thousand dollars will get you around five shares of Johnson & Johnson stock. 2. Medtronic is two years shy of being a Dividend King Medtronic has increased its dividend annually for 48 consecutive years. That's not as good as the streak Johnson & Johnson has built, but it is still pretty darn impressive. Medtronic is focused exclusively on medical devices, and it has a dividend yield of roughly 3.1% today. Like Johnson & Johnson, Medtronic is one of the largest players in the sectors it serves. Medtronic's dividend yield also happens to be historically high right now. Unlike with Johnson & Johnson, however, the problems here don't involve a large class action lawsuit. Medtronic's growth has slowed down, thanks at least in part to a period in which few new products were being introduced. Management is working to fix the issue. For starters, new products are again starting to come to market (innovation is lumpy, so this isn't shocking). The company is also attempting to refocus around its most desirable businesses. The end result is likely to be a more profitable and faster-growing company. But for now, Wall Street remains in a "show me" mood, which is an opportunity for buy-and-hold dividend investors to jump aboard an industry-leading medical device maker while it has a historically attractive dividend yield. A $1K investment will net you roughly 10 shares of Medtronic. 3. Merck's dividend record is good, but not kingly Merck is one of the largest pharmaceutical companies on the planet. As noted, innovation is lumpy, and that's particularly true when it comes to drugs. Add in the fact that drug patents only allow exclusivity for so long, and there's always a cliff somewhere down the line for drugmakers with blockbuster products. This is the nature of Merck's business, and there's nothing that can be done about it. Sometimes it just takes a little bit longer than hoped to find a new drug to replace the ones that are losing patent protections. What's actually impressive is that, despite the ups and downs, Merck has managed to keep its dividend growing over time. That hasn't happened every single year -- there have been some lengthy periods when the dividend was static. But generally higher over time is still quite attractive when you add it to a historically high 3.9% or so dividend yield. There's no telling when Merck will find its next blockbuster. It may develop it in-house, or it might buy a company to acquire an attractive drug. But history suggests that buying and holding this giant drugmaker has been a win for dividend lovers with a holding period of "forever." Investing $1,000 here will allow you to buy about 11 shares of Merck. What are you really buying? Johnson & Johnson, Medtronic, and Merck are all high-yield healthcare stocks with strong dividend records. But that's not really all you're buying here. The truth is, healthcare is a very complex sector, and these three industry giants are standout businesses. You may not be expert enough in healthcare to keep up with the innovation in the industry, but these three companies are experts. In other words, you're getting well-run businesses that are doing the heavy lifting in the healthcare sector so you don't have to be an expert. Along with that, you're getting attractive dividend yields backed by solid dividend histories. Should you buy stock in Johnson & Johnson right now? Before you buy stock in Johnson & Johnson, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Johnson & Johnson wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 28, 2025 Reuben Gregg Brewer has positions in Medtronic. The Motley Fool has positions in and recommends Merck. The Motley Fool recommends Johnson & Johnson and Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever was originally published by The Motley Fool

Ray Dalio Says 15% In Bitcoin Or Gold May Be Essential As Fiat Currencies Face Devaluation Risks
Ray Dalio Says 15% In Bitcoin Or Gold May Be Essential As Fiat Currencies Face Devaluation Risks

Yahoo

time9 minutes ago

  • Yahoo

Ray Dalio Says 15% In Bitcoin Or Gold May Be Essential As Fiat Currencies Face Devaluation Risks

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Billionaire investor Ray Dalio advised a 15% portfolio allocation to Bitcoin (CRYPTO: BTC) or gold, citing mounting U.S. debt concerns and potential currency devaluation risks. What Happened: The Bridgewater Associates founder warned of a 'classic devaluation' scenario similar to the 1970s or 1930s in an appearance on the Master Investor Podcast, where fiat currencies could decline together against hard assets. 'If you were neutral on everything and optimizing your portfolio for the best return-to-risk ratio, you would have about 15% of your money in gold or Bitcoin,' Dalio stated. Don't Miss: 7,000+ investors have joined Timeplast's mission to eliminate microplastics— This AI-Powered Trading Platform Has 5,000+ Users, 27 Pending Patents, and a $43.97M Valuation — You Can Become an Investor for Just $500.25 Dalio expressed a strong preference for gold over Bitcoin, previously describing the precious metal as the 'purest play' for a store of value. Gold currently ranks as the second-largest reserve currency globally after the U.S. dollar, he noted. The billionaire holds both assets but maintains significantly larger gold positions than Bitcoin allocations. Why It Matters: The veteran investor highlighted critical fiscal challenges facing the United States. Federal government debt stands at 125% of GDP, with the fiscal deficit reaching 7% of GDP—the highest among industrialized nations. Dalio proposed a '3% solution' requiring immediate action to reduce the deficit from 7.5% to 3% of GDP through combined tax increases and spending cuts. While acknowledging Bitcoin's perceived value as alternative money with limited supply and global transaction benefits, Dalio questioned its effectiveness as a reserve Next: $100k+ in investable assets? Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes – no cost, no obligation. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Image via Shutterstock This article Ray Dalio Says 15% In Bitcoin Or Gold May Be Essential As Fiat Currencies Face Devaluation Risks originally appeared on

UnitedHealth Stock Is Having Its Worst Year Since 2008. Can It Recover?
UnitedHealth Stock Is Having Its Worst Year Since 2008. Can It Recover?

Yahoo

time9 minutes ago

  • Yahoo

UnitedHealth Stock Is Having Its Worst Year Since 2008. Can It Recover?

Key Points It isn't typical for UnitedHealth stock to finish a year lower than it started, let alone be down more than 40% as it is right now. Rising costs and uncertainty around healthcare reform are just a couple of the issues plaguing the stock. It's trading around multiyear lows, however, and is arguably a cheap buy. 10 stocks we like better than UnitedHealth Group › For years UnitedHealth Group (NYSE: UNH) has normally been a reliable dividend stock. But an abysmal start to 2025 has wiped out many of the gains that investors have achieved in recent years, with its five-year return now in negative territory. Year to date, the stock has fallen by nearly 45%, which is by no means normal for the healthcare stock. In fact, this is the worst it has performed since the Great Recession, when it tumbled by more than 54% in 2008. The big questions many investors are likely asking today are: Can it recover? Or is there more of a downfall to come for this once seemingly unstoppable stock? Big declines aren't the norm for UnitedHealth The past few years haven't been all that great for UnitedHealth, but by and large, this has been a fairly strong stock to own. It has typically outperformed the market. And outside of 2024 -- when it was down 4% -- the last time it finished a year in the red was (as noted) back in 2008, when the U.S. economy was in the midst of the Great Recession and the stock lost more than half of its value. Not only has UnitedHealth normally been a safe stock, it's also been a tremendous growth stock. Consider that if you invested $10,000 into its shares at the end of 2003, then 20 years later your investment would have been worth $181,000. But if you hung on until now, that investment would have fallen to a value of $101,000. While that's still a good return, it spotlights just how significant the decline has been this year, for a stock that's typically known for being a solid long-term investment. Still, the past doesn't predict the future. Why the company might face a tough road ahead The problem with UnitedHealth right now is that it's facing many challenges. Medical costs are up, and there's a lot of uncertainty in healthcare as the federal government looks to cut costs. Meanwhile, the Department of Justice is reportedly looking into UnitedHealth's billing practices. The danger is that the company may face financial repercussions and other headwinds, such as having to change its practices -- or at the very least, incurring higher-than-typical costs due to greater utilization rates. The latter, however, may be a shorter-term trend. Either way, this is a business known for consistently growing its operations, and that may not be a sure thing anymore. While UnitedHealth generated a healthy profit of more than $14.4 billion on revenue of $400.3 billion in 2024, investor concerns about long-term growth appear to be weighing on the stock. In May, the company suspended its outlook for the year; it also announced a change in CEO, with Andrew Witty stepping down for personal reasons and former CEO Stephen Hemsley taking over. Should you buy UnitedHealth stock today? While UnitedHealth stock has done well in previous years, that doesn't mean that it's a surefire bet to rebound soon. The good news is that it still has solid fundamentals. Since it's a key health insurer in the U.S., I'd be hesitant to count it out in the long run. There's some near-term risk and even some long-term uncertainty about how all the changes in the healthcare industry might pan out. But the stock is trading at levels it hasn't been at since 2020, and its valuation is just 12 times its trailing earnings. I think that gives it a good enough margin of safety at its current price, and that buying it today might prove to be a solid move. As long as you're willing to be patient, this can be a good stock to buy and hold. Should you buy stock in UnitedHealth Group right now? Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 28, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy. UnitedHealth Stock Is Having Its Worst Year Since 2008. Can It Recover? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store